Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-12-11
2009-12-15
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S337000, C514S359000, C514S646000, C514S650000, C514S655000, C514S810000
Reexamination Certificate
active
07632843
ABSTRACT:
The present invention belongs to the field of pharmaceutical industry and relates to a new method for the treatment of psychostimulant addiction, in particular cocaine addiction, or pharmaceutically acceptable acid addition salts thereof, with a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propy-nyl)-6-methyl-8β-aminomethylergo-line in the form of free base or in the form of pharmaceutically acceptable addition salt, in particular the bimaleate salt, as well as pharmaceutical compositions containing said compound. In literature, the compound is also known under code LEK-8829. More particularly, present invention relates to a novel method of treatment for reduction of abstinence symptoms after cocaine withdrawal and for suppression the symptoms of craving for cocaine withdrawal and for suppression the symptoms of craving for cocaine reinforcement, and to the use of said active substance for the preparation of the pharmaceutical composition for the treatment of cocaine addiction. In addition to the treatment of cocaine addiction, the present invention also relates to the method for treatment of the addiction with amphetamine, methamphetamine, dextroamphetamine, 3,4-methylenedioxymethamphetamine and pemoline or acid addition salts thereof.
REFERENCES:
patent: 4935429 (1990-06-01), Dackis et al.
patent: 5430031 (1995-07-01), Brambilla et al.
patent: 5441961 (1995-08-01), Cohen et al.
patent: 5480885 (1996-01-01), Rucman et al.
patent: 01/41763 (2001-06-01), None
Smelson et al, “Risperidone Decreases Craving and Relapses in Individuals with Schizophrenia and Cocaine Dependence”, Can J Psychiatry, vol. 47, No. 7, Sep. 2002.
Pulvirenti et al., “Characterization of the Effects of the Partial Dopamine Agonist Terguride on Cocaine Self-Administration in the Rat”, Journal of Pharmacology and Experimental Therapeutics, 1998, 286, pp. 1231-1238.
Pulvirenti et al., Dopamine receptor agonists, partial agonists, and psychostimulant addiction, Trends Pharmacol Sci 1994, 15, pp. 374-379.
L Handelsman et, al, Am J. Addict, vol. 6 (1) “Bromocriptine for Cocaine Dependence”, A controlled clinical trial.
Milivojevic et al., “A Novel Ergoline Derivative LEK-8829 Attenuates Cocaine-Induced Reinstatement of Cocaine-Seeking Behavior”, Behavioural Pharmacology, vol. 14, No. Suppl. 1, p. S55 (2003).
Glavan et al., “Modulation of Neuroleptic Activity of 9,10-didehydro-N-methyl-(2-propynyI)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 Intrinsic Activity in Hemi-Parkinsonian Rates”, Molecular Pharmacology, vol. 61, No. 2, pp. 360-368 (2002).
Zivin et al., “Antiparkinsonian Potential of Interaction of LEK-8829 with Bromocriptine”, European Journal of Pharmacology, Vol. 349, No. 2-3, pp. 151-157 (1998).
Bole-Vunduk Breda
Krisch Igor
Milivojevic Natasa
Rucman Rudolf
Urleb Uros
Javanmard Sahar
Lek Pharmaceuticals d.d.
Luedeka Neely & Graham P.C.
Padmanabhan Sreeni
LandOfFree
Treatment of psychostimulant addiction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of psychostimulant addiction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of psychostimulant addiction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4102653